Tethered Capsule Endoscope in Screening Patients With Barrett Esophagus
Primary Purpose
Barrett Esophagus
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Survey Administration
Tethered Capsule Endoscope
Sponsored by
About this trial
This is an interventional device feasibility trial for Barrett Esophagus
Eligibility Criteria
Inclusion Criteria:
- Ability and willingness to provide written informed consent
- Scheduled for endoscopic screening and/or evaluation of Barrett's esophagus
Exclusion Criteria:
- Previous history of a swallowing disorder, such as scleroderma, achalasia, esophageal stricture or esophageal diverticulum
- Symptoms of dysphagia
- Suspicion or known history of gastrointestinal obstruction
- History of prior surgery on the oropharynx, neck, esophagus, or stomach
- Current diagnosis of cancer, unstable cardiovascular disease, end-stage liver or kidney disease, or other major medical illness
- Currently taking anticoagulant medications or clopidogrel
- Major physical disability which would prevent subject from transferring from a chair to a bed and sitting in an upright position
- Inability to abstain from taking anything by mouth for at least 6 hours
- Currently pregnant
- Expected to undergo magnetic resonance imaging (MRI) within two weeks following the study procedure
Sites / Locations
- Fred Hutch/University of Washington Cancer Consortium
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Screening (TCE)
Arm Description
Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
Outcomes
Primary Outcome Measures
Consistent image quality
Consistent image quality defined as no significant degradation of lateral spatial resolution [line pairs per mm] and axial depth of focus [mm], maximum field of view [degrees cone angle], and color fidelity [qualitatively matches color chart] when measured after use in the clinic using color and resolution test targets and a test chamber to measure field of view. The standard care EGD will be digitally recorded to allow for review and comparison to the TCE procedure by a blinded, expert endoscopist.
Consistent usability defined as no significant change to the tolerance rating given by the patient by survey, and ease of use by the physician by survey, and time for completing the examination
Incidence of adverse events associated with TCE use
Secondary Outcome Measures
Full Information
NCT ID
NCT02729948
First Posted
March 25, 2016
Last Updated
January 18, 2019
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
1. Study Identification
Unique Protocol Identification Number
NCT02729948
Brief Title
Tethered Capsule Endoscope in Screening Patients With Barrett Esophagus
Official Title
Use of a Tethered Capsule Endoscope in Screening for Barrett's Esophagus
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
July 28, 2016 (Actual)
Primary Completion Date
August 3, 2017 (Actual)
Study Completion Date
August 3, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This pilot clinical trial studies how well tethered capsule endoscope works in screening patients with Barrett esophagus (BE), a condition where the lining of the esophagus has changed or has been replaced with abnormal cells that may lead to cancer also called esophageal cancer. In an attempt to prevent the progression from BE to esophageal cancer, patients undergo a standard procedure called esophagogastroduodenoscopy (EGD) where patients are sedated and the doctor uses an endoscope to examine the tissue in the esophagus. Tethered capsule endoscope is a tiny capsule with a laser scan inside and a very thin cord attached to it. Patients swallow the capsule and the thin cord keeps the capsule in specific area in the esophagus. After pictures of the lining of esophagus are taken, the capsule is removed using the thin cord. Tethered capsule endoscope may be able to identify tissue changes in patients with BE without the need for sedation or anesthesia, thus eliminating the associated risks and costs associated with EGD.
Detailed Description
PRIMARY OBJECTIVES:
I. Evaluate image quality and usability of the tethered capsule endoscope after repeated clinical use and reprocessing.
II. Evaluate safety issues associated with the use of the device for this subject population - was there any noticeable difference from prior study of subjects at high risk of Barrett's esophagus using the same device, but without reprocessing.
SECONDARY OBJECTIVES;
I. Study other specified device characteristics or device application considerations.
II. Obtain preliminary data for use in designing a subsequent pivotal study of the device.
OUTLINE:
Patients swallow the tethered capsule endoscope (TCE) and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Barrett Esophagus
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Screening (TCE)
Arm Type
Experimental
Arm Description
Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
Intervention Type
Other
Intervention Name(s)
Survey Administration
Intervention Description
Ancillary studies
Intervention Type
Device
Intervention Name(s)
Tethered Capsule Endoscope
Other Intervention Name(s)
TCE
Intervention Description
Undergo TCE
Primary Outcome Measure Information:
Title
Consistent image quality
Description
Consistent image quality defined as no significant degradation of lateral spatial resolution [line pairs per mm] and axial depth of focus [mm], maximum field of view [degrees cone angle], and color fidelity [qualitatively matches color chart] when measured after use in the clinic using color and resolution test targets and a test chamber to measure field of view. The standard care EGD will be digitally recorded to allow for review and comparison to the TCE procedure by a blinded, expert endoscopist.
Time Frame
At the conclusion of TCE exam (day 1)
Title
Consistent usability defined as no significant change to the tolerance rating given by the patient by survey, and ease of use by the physician by survey, and time for completing the examination
Time Frame
At the conclusion of TCE exam (day 1)
Title
Incidence of adverse events associated with TCE use
Time Frame
Up to 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ability and willingness to provide written informed consent
Scheduled for endoscopic screening and/or evaluation of Barrett's esophagus
Exclusion Criteria:
Previous history of a swallowing disorder, such as scleroderma, achalasia, esophageal stricture or esophageal diverticulum
Symptoms of dysphagia
Suspicion or known history of gastrointestinal obstruction
History of prior surgery on the oropharynx, neck, esophagus, or stomach
Current diagnosis of cancer, unstable cardiovascular disease, end-stage liver or kidney disease, or other major medical illness
Currently taking anticoagulant medications or clopidogrel
Major physical disability which would prevent subject from transferring from a chair to a bed and sitting in an upright position
Inability to abstain from taking anything by mouth for at least 6 hours
Currently pregnant
Expected to undergo magnetic resonance imaging (MRI) within two weeks following the study procedure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Saunders
Organizational Affiliation
Fred Hutch/University of Washington Cancer Consortium
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fred Hutch/University of Washington Cancer Consortium
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Tethered Capsule Endoscope in Screening Patients With Barrett Esophagus
We'll reach out to this number within 24 hrs